ArticleBMC urology2024
Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019.
Article in BMC urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Doxazosin versus tamsulosin for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic literature review and network meta-analysis.World journal of urology · 2026Pooled it
- Neurogenic lower urinary tract dysfunction in ageing men with spinal cord injury.Nature reviews. Urology · 2026Review
- The gut-prostate axis in benign prostatic diseases: Mechanistic pathways and therapeutic implications.iScience · 2026Review
- Analysis of Notch1 and Notch3 Signaling Pathway Components in Benign Prostatic Hyperplasia and Prostate Cancer Patients.Journal of clinical laboratory analysis · 2026Article
- Frailty burden and symptomatic BPH/LUTS in aging men: evidence from two nationally representative population-based studies.World journal of urology · 2026Article
- Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men.Journal of global health · 2026Article
- Sport, genetic susceptibility, and the risk of benign prostatic hyperplasia: a large prospective cohort study.World journal of urology · 2026Article
- Holmium laser enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: evidence from a Korean retrospective analysis using the Common Data Model.Prostate international · 2026Article
- An intelligent wearable device based on electrical impedance tomography for dynamic and accurate monitoring of voiding function in patients with benign prostatic hyperplasia: protocol for a single-centre self-controlled diagnostic consistency study.Translational andrology and urology · 2026Article
- Uroprotective effect of diarylpropionitrile versus finasteride on rat model of testosterone-induced prostatic hyperplasia.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients.Investigative and clinical urology · 2026Article
- Fibroblasts promote the progression of benign prostatic hyperplasia through colony-stimulating factor 1 receptor-mediated RTK signaling in prostatic epithelial cells.Molecular biomedicine · 2025Article
- N-butyl cyanoacrylate glue application in prostate artery embolization for benign prostatic hyperplasia: a systematic review of safety and efficacy.CVIR endovascular · 2025Review
- Airborne chloride exposure and benign prostatic hyperplasia risk.BMC research notes · 2025Article
- Preoperative pelvimetric and prostatic measurements as predictors of intraoperative blood loss in open transvesical prostatectomy: a retrospective study.BMC surgery · 2025Article
- From Prostate Enlargement to Bladder Stone: Large Bladder Stone as a Complication of Long-Standing BPH: A Case Study.Clinical case reports · 2025Article
- Ultrasound-guided Transperineal Prostate Thermal Ablation (TPTA) for Benign Prostatic Hyperplasia: Feasibility of an Outpatient Procedure using Radiofrequency Ablation.Cardiovascular and interventional radiology · 2025Observational
- Transurethral resection of the prostate in the extreme elderly (≥ 85 years): treatment success, morbidity and survival.World journal of urology · 2025Article
- Prescription Trends of Initial Pharmacotherapy for Benign Prostatic Hyperplasia Among Treatment-Naïve Patients in South Korea: A Retrospective Analysis.Lower urinary tract symptoms · 2025Article
- Modulating Benign Prostatic Hyperplasia Through Physical Activity-The Emerging Role of Myokines: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign prostatic hyperplasia (BPH) is a prevalent urological disease in elderly males. However, few studies have estimated the temporal and spatial distributions of the BPH burden in male adults aged 60 years and over at the global, national, and regional scales.
methodsLeveraging the Global Burden of Disease, Injuries, and Risk Factors Study, we estimated the global epidemiological trends in the prevalence, incidence, and disability-adjusted life-years (DALYs) of BPH in 204 countries and 21 regions and 5 sociodemographic index (SDI) regions in males aged 60 years and over between 1990 and 2019. The average annual percentage changes (AAPCs) in age-specific rates were estimated to quantify overall trends. We estimated the contribution of population aging and epidemiological alterations in disease burden via composition analysis.
resultsOver the past three decades, the global prevalent cases, incident cases and DALYs of BPH have increased, ranging from 118.78 to 121.22%. The global number of prevalent BPH cases reached 79 million in people aged 60 years and older in 2019. The prevalence, incidence, and DALYs rates gradually increased, with AAPCs of 0.02, 0.02, and 0.01, respectively. Low-middle, middle, and low SDI regions experienced rapid increases in the number of prevalent cases of BPH. In 2019, China, India, and United States of America bore the largest burden of prevalent cases among people aged 60 years and over. The three regions with the highest prevalence rates of BPH were Eastern Europe, Central Latin America, and Andean Latin America. The increased prevalence was attributed to population growth (94.93%), epidemiological changes (3.45%), and aging (1.62%), globally.
conclusionsBPH is a global health issue that imposes substantial economic burdens on most countries, particularly males aged 60 years and over. Effective health decisions are imperative for BPH prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.